Nicox's China Filing Is Real Progress — Just Don't Mistake It for a Free-Cash-Flow Story

On August 10, 2026, Nicox's Chinese partner Ocumension handed China's drug regulator an application for NCX 470, the eye drop that is the small French ophthalmology company's one genuine shot at stand-alone revenue. The filing is the second big-market submission inside six weeks: Kowa, Nicox's U.S. partner, had filed the same molecule with the FDA in early July, and the FDA has already set a decision date of April 30, 2027. A drug that a year ago was still finishing its pivotal trials is now formally under review in two of the world's largest drug markets.

The company behind it is tiny. Nicox trades on Paris's small-cap exchange — not on U.S. exchanges — at roughly €0.37 a share, a market cap around €35 million. So this is not headline material most American investors will ever see. But the structure of the story is worth understanding, because it shows what "progress" actually means for a company with no earnings and no cash flow from operations: fewer hopes and more paid milestones.

NCX 470 is a nitric-oxide-donating version of bimatoprost, an established glaucoma drug, aimed at lowering intraocular pressure in open-angle glaucoma or ocular hypertension. The Chinese application is supported by the same phase 3 program — the Mont Blanc and Denali trials — as the U.S. filing, and the Denali trial deliberately included Chinese clinical sites so one data package could serve both regulators. In those trials Nicox reported IOP reductions of up to roughly 10 mm Hg, and in earlier work the higher doses beat generic latanoprost — the cheap, ubiquitous standard of care — on pressure lowering. That is the competitive point that matters: a new glaucoma drug has to out-perform a drug that costs pennies, or it has little reason to exist.

The financial bridge is milestone cash, not free cash flow

Here is the honest part. Nicox is not the kind of business I usually spend time on. It has no free cash flow — it loses money and funds itself by selling the rights to its drugs and issuing equity. That means the discipline that normally anchors an investment case — "show me the free cash flow" — does not apply. When free cash flow is absent, the only honest thing to do is name the alternative metric that has to carry the case, and here that metric is contractual milestone cash plus a balance sheet that no longer looks like it is about to run dry.

The trajectory is not subtle. At the end of 2025 Nicox held €4.1 million in cash. By August 31, 2026, that was roughly €8.4 million — the Kowa U.S. filing alone triggered a €3 million milestone payment — enough for management to say it is funded beyond the first quarter of 2028. The company's revenue is built on these step payments: 2025 revenue climbed to €16.8 million from €7.9 million a year earlier, almost entirely on U.S. license milestones, and the net loss narrowed from €22.4 million to €2.4 million. None of that makes Nicox profitable, but it changes the question from "will it run out of cash before approval?" to "what happens if approval arrives?"

The China leg has a structural advantage. Ocumension paid Nicox €18 million in license fees for rights across China, Korea and Southeast Asia, funded half of the Denali trial, and holds a meaningful stake in Nicox itself. When the partner writing the checks also owns a piece of you and brings its own Chinese sales force, the incentives line up unusually well: both sides lose if the approval stalls. Nicox will collect tiered royalties of roughly 6% to 12% on sales once the drug reaches market, on top of the milestone stream.

Why the market still prices the old story

For all the filings, Nicox still looks like a beaten-down, single-asset biotech, because in many ways it is. It is up about 65% over the past year — but from a base near €0.28, and a 65% move off a depressed floor leaves it at a €35 million valuation for a company whose main asset may not generate meaningful revenue before late 2027. The market is still pricing the old story: a hope that a small molecule might someday make it. The phase 3 data, the two major-market filings, and the repaid runway are the operating proof that the story has moved past hope and into execution.

The risk, plainly

The bear case is not hard to build, and it deserves more weight than the milestone wins. There is still no free cash flow, so dilution is structural: the company raises money with warrants, convertible bonds and capital increases — exactly the kind of mechanics that grind down per-share value. The business depends on one drug, and that drug must clear regulatory review, then take on latanoprost and other entrenched generics in a market where pricing power is weak. China's approval can reasonably take 12 to 18 months from this filing, and it is expected to trail the United States.

So name the break condition in advance. The case is falsified if the U.S. or China review hits a serious setback, if the approval milestone cash does not arrive as scheduled, or if the cash runway erodes before revenue starts — because that would force another dilutive raise at a low price. If approvals land and the milestone and royalty streams arrive on schedule, the rerating math follows mechanically from a low market cap. Until one of those two things happens, what you are buying is not a cash-generating business. You are buying a funded, derisking drug program with milestone cash as the only hard proof — and a clear, specific tripwire for when that proof fails.